Effect of dipeptidyl peptidase-4 inhibitors linagliptin on the expression of serum pigment epithelium-derived factor in type 2 diabetes patients

Abstract

To investigate the difference in serum pigment epithelium-derived factor(PEDF)among type 2 diabetic patients before and after use of dipeptidyl peptidase-4 inhibitors linagliptin for treatment, and to explore the correlation of serum PEDF with lipids, body mass index, and HbA1C. 39 patients with recently diagnosed type 2 diabetes and 30 healthy individuals were enrolled. Baseline weight, waist circumference, body mass index, fasting plasma glucose, HbA1C, serum glutamic-pyruvic transaminase, glutamic oxaloacetic transaminase, total cholesterol, triglyceride, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol(LDL-C), and PEDF measured by enzyme linked immunosorbant assay were determined both in the diabetic and control subject. The treatment group was treated with oral linagliptin 5 mg/d for six month, serum PEDF and clinical parameters were determined in the diabetic group during 6 months of treatment.(1)PEDF levels were found to be comparable with the controls(P=0.584); LDL-C and waist circumference showed positive correlation with PEDF(P<0.05 or P<0.01). (2)PEDF level was significantly increased in patients with type 2 diabetes after linagliptin treatment [(3.21±1.91 vs 2.45±1.53)μg/ml, P<0.01]. Serum PEDF level in patients with type 2 diabetes was similar to that of healthy controls with associated LDL-C and waist circumference. After linagliptin treatment, serum PEDF level was raised, suggesting that it may have certain protective effect for diabetic vascular complications. (Chin J Endocrinol Metab, 2015, 31: 696-699) Key words: Diabetes mellitus, type 2; Pigment epithelium-derived factor; Dipeptidyl peptidase-4 inhibitors